# Alltrna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alltrna

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.alltrna.com
- Total disclosed funding: $134M
- Latest round: Series B (Aug 9, 2023)
- Investors on record: 1

## About

Alltrna, Inc., based in the US, specializes in developing universal tRNA medicines that aim to restore disrupted protein production in a variety of genetic diseases.Founded in 2018 and headquartered in Cambridge, US, Alltrna, Inc. focuses on utilizing engineered transfer RNA (tRNA) technology to address genetic conditions linked to nonsense mutations. The company has secured a total of USD 109.00 mn in funding through two deals, with the most recent being a Series B round on August 9, 2023, led by Flagship Pioneering. Michelle Werner serves as the CEO of the company.Alltrna specializes in developing universal tRNA medicines designed to restore disrupted protein production across a wide range of genetic diseases linked by shared underlying genetic mutations. Their core technology involves engineered tRNA molecules that can correct nonsense mutations, allowing for the delivery of necessary amino acids that produce full-length proteins essential for cellular function. The therapeutic platform targets multiple genetic conditions arising from premature termination codons (PTCs), catering to a diverse patient demographic, including individuals suffering from rare diseases globally, particularly in North America, Europe, and parts of Asia.Alltrna generates revenue through partnerships with research institutions and pharmaceutical companies focused on genetic therapies. Licensing agreements allow Alltrna to provide its advanced tRNA technology to partners in exchange for milestone payments and royalties based on successful therapy development and commercialization, underpinned by proprietary therapies leveraging Alltrna's innovative tRNA platform.Following the Series B funding of USD 109.00 mn raised on August 9, 2023, Alltrna plans to utilize this capital to expand its tRNA sequences and enhance product testing. The company is strategically focused on developing new products aimed at treating genetic conditions caused by PTCs, with ambitions to penetrate additional global markets where genetic disorders are prevalent.

## Funding rounds

- Series B, Aug 9, 2023, $109M — Flagship Pioneering
- Series A, Nov 9, 2021, $25M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B